Oslo – May 23, 2008 – DiaGenic ASA and SRL Ranbaxy Ltd. today announced that they have signed a commercial agreement to commence marketing DiaGenic's breast cancer test in India. This development follows rapidly from a presentation at The Federation of Obstetrics and Gynecology Societies of India (FOGSI) annual meeting in New Delhi in February where the interim results of a large Indian clinical study on this test were presented.
DiaGenic has developed a patient friendly diagnostic test for early detection of breast cancer in which a woman merely has to give a small blood sample, which is then subjected to sophisticated laboratory analysis to detect changes in gene expression. The interim results from the Indian study showed that the gene set, previously identified in Scandinavian and US cohorts, also had similar good diagnostic and predictive performance in the Indian population. The test is not affected by ethnic variation or menopausal state of the patient, allowing for widespread use to diagnose breast cancer at an early stage.
DiaGenic has developed a patient friendly diagnostic test for early detection of breast cancer in which a woman merely has to give a small blood sample, which is then subjected to sophisticated laboratory analysis to detect changes in gene expression. The interim results from the Indian study showed that the gene set, previously identified in Scandinavian and US cohorts, also had similar good diagnostic and predictive performance in the Indian population. The test is not affected by ethnic variation or menopausal state of the patient, allowing for widespread use to diagnose breast cancer at an early stage.
Continue reading: http://www.diagenic.com/site.php?id=pr&year=2008&id1=41281041797564
0 comments:
Post a Comment